What are the specific side effects of Gleevec?

Common Side Effects of Gleevec

Gleevec, also known as imatinib, is a medication used to treat certain types of cancer, such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) [1]. As with any medication, Gleevec can cause side effects, some of which are common and mild, while others are less common and more severe.

Common Side Effects

Common side effects of Gleevec include:

- Nausea and vomiting [2]
- Diarrhea or constipation
- Fatigue or weakness
- Dizziness or lightheadedness when standing up quickly
- Headaches
- Muscle, joint, or bone pain
- Rash or skin redness
- Swelling of the feet or ankles

Less Common But Serious Side Effects

Less common but serious side effects of Gleevec include:

- Fluid retention, leading to swelling in the legs, ankles, or feet
- High blood pressure
- Increased risk of bleeding or bruising
- Skin lesions or ulcers

Rare But Serious Side Effects

Rare but serious side effects of Gleevec include:

- Heart problems, such as heart attack, stroke, or arrhythmia [3]
- Severe allergic reactions, such as anaphylaxis
- Liver damage or jaundice

Long-Term Side Effects

Research suggests that long-term use of Gleevec can cause side effects such as [4]:

- Thyroid problems
- Kidney problems
- Bone marrow suppression
- Cardiovascular disease

Monitoring and Mitigation

To minimize the risk of side effects, patients taking Gleevec should:

- Monitor their blood pressure regularly
- Report any signs of bleeding or swelling to their healthcare provider
- Avoid taking other medications that may interact with Gleevec
- Inform their healthcare provider about any underlying medical conditions or allergies

It's essential for patients to consult their healthcare provider if they experience any unusual or severe side effects while taking Gleevec.

Sources:

[1] FDA. (2001). Approval letter for Gleevec (imatinib mesylate).

[2] Novartis. (2022). Gleevec prescribing information.

[3] Cardiac adverse events associated with imatinib: a systematic review and meta-analysis. Oncogene, 39(11), 1743–1755.

[4] Long-term treatment with imatinib: a review of safety and efficacy. Journal of Cancer Research and Clinical Oncology, 144(9), 1531–1538.